DSpace Collection:http://elea.unisa.it/xmlui/handle/10556/45142026-05-29T21:45:20Z2026-05-29T21:45:20ZWithholding and withdrawing in real lifePiazza, Ornellahttp://elea.unisa.it/xmlui/handle/10556/45182025-04-30T15:29:39Z2018-01-01T00:00:00ZTitle: Withholding and withdrawing in real life
Authors: Piazza, Ornella2018-01-01T00:00:00ZTreatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patientsBracale, Umberto MarcelloDi Filippo, MathildeDe Capua, AntonioVanni, LindaNarese, DonatellaPecoraro, FeliceGiribono, Anna MariaBracale, Renatahttp://elea.unisa.it/xmlui/handle/10556/45172025-04-30T15:29:37Z2018-01-01T00:00:00ZTitle: Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients
Authors: Bracale, Umberto Marcello; Di Filippo, Mathilde; De Capua, Antonio; Vanni, Linda; Narese, Donatella; Pecoraro, Felice; Giribono, Anna Maria; Bracale, Renata
Abstract: Angioplasty with drug-coated balloon
(DCB) is an emerging and reliable method for the
treatment of femoro-popliteal lesions. We report
our experience with the Stellarex™ DCB in the
first 50 patients.
Methods - From July 2015 to November 2017, 50
patients (41 M, 9F), medium age (64 ± 7.4 year)
were subject to 33 angioplasties (PTAs) for
femoro-popliteal lesions with a paclitaxel-coated
balloon (Stellarex™). Based upon clinical data
sixteen patients had severe claudication (56% -
Rutherford class 3); ten patients suffered from
ischemic rest pain (34% - Rutherford class 4); and
five presented minor tissue loss (10% -
Rutherford class 5). 42% of patients showed
femoro-popliteal lesion TASC-II B, and 58%
presented lesions pertaining to TASC-II C.
Results - Immediate technical success was 100%
without perioperative complications. Primary
patency rate was 94% at twelve months. In three
cases restenosis (6%) was detected within a year
from procedure, and a further PTA DCB was
performed with primary assisted patency rates of
100% at twelve months. Two patients underwent
major lower limb amputation. Three patients died
during follow-up and one patient was lost at
follow-up.
Conclusion - DCB angioplasty with Stellarex™
is a viable alternative to traditional endovascular
procedures proving satisfactory primary patency
rates at twelve months. Based on our experience,
treatment with DCB is a first choice technique for
non-complex de novo lesions of the femoro –
popliteal tract.2018-01-01T00:00:00Z